161
Participants
Start Date
May 17, 2019
Primary Completion Date
September 15, 2022
Study Completion Date
September 15, 2022
Gefapixant 45 mg twice daily (BID)
Gefapixant 45 mg tablet to be administered orally BID
Gefapixant 15 mg BID
Gefapixant 15 mg tablet to be administered orally BID
Placebo
Placebo tablet administered orally BID
Gefapixant 45 mg BID
Gefapixant 45 mg tablet to be administered orally BID
Peking University Third Hospital ( Site 5005), Beijing
ShengJing Hospital of China Medical University ( Site 5024), Shenyang
Shanghai General Hospital ( Site 5010), Shanghai
The First Affiliated Hospital of Zhejiang University ( Site 5014), Hangzhou
The First Affiliated Hospital of Nanchang University ( Site 5012), Nanchang
The First Affiliated Hospital of Fujian Medical University ( Site 5017), Fuzhou
The First Affiliated Hospital of Guangzhou Medical University ( Site 5000), Guangzhou
Inner Mongolia Autonomous Region Hospital ( Site 5018), Hohhot
Merck Sharp & Dohme LLC
INDUSTRY